@ash-shoamanesh
Stroke Neurologist at Hamilton Health Sciences Associate Professor of Medicine (Div. of Neurology) at McMaster University Director of Hemorrhagic Stroke Research Program & Senior Scientist at the Population Health Research Institute
We are absolutely thrilled to share that the OCEANIC-STROKE trial has successfully met its primary efficacy & safety endpoints.
These landmark findings address a major unmet need in the ~5M people worldwide who have a new non-cardioembolic ischemic stroke each year.
www.bayer.com/media/en-us/...
Proudly sharing our publication featured in NY Times: 17 Ways to Cut Your Risk of Stroke, Dementia and Depression All at Once www.nytimes.com/2025/04/23/w...
High lipoprotein(a) levels, defined as 50 mg/dL or greater, are associated with increased rates of atherosclerotic cardiovascular disease events and all-cause mortality. This JAMA Insights discusses lipoprotein(a).
#MedSky https://ja.ma/42Ma9Wv
Exciting News!
🚨 Save the Date for the 2026 Canadian Stroke Congress
🗻 Banff, Alberta
📅 May 23-26, 2026
More details coming soon at www.CanadianStroke.ca
#CSC2026 #StrokeCongress26 #SavetheDate #StrokeRecovery #StrokeResearch
The ICH-ADAPT2 trial results were just published in
@jama.com Neurology. DWI lesions are observed in ~33% of patients with acute ICH. Our findings do not support a causal relationship between intensive BP lowering and DWI lesions in these patients.
jamanetwork.com/journals/jam...
This achievement would not have been possible without the commitment and expertise of our exceptional network of collaborators across 700+ sites in 38 countries. Thank you for your unwavering dedication and partnership!
We look forward to sharing the results once follow-up is complete — stay tuned!
Thrilled to share that the OCEANIC-STROKE trial (NCT05686070) led by PHRI & Bayer AG, has successfully completed enrolment of over 12,300 participants with non-cardioembolic ischemic #stroke over a recruitment period of only 26-months!
🔗https://phri.ca/oceanicstroke/
For those interested and who were unable to join us at @americanheart.bsky.social #ISC2025 please find the recording of our @medscape.com webinar on the rise of new anticoagulants for stroke prevention here:
www.youtube.com/watch?v=D8f0...
@macdeptmed.bsky.social
Absolutely honoured to be delivering the inaugural Ralph Sacco Distinguished Lecture at the @universityofmiami.bsky.social 58th Neurology Update & Stroke Intensive Review. Huge thanks to Drs. Negar Asdaghi & Jose Romano for their generous invitation and gracious hospitality!
@macdeptmed.bsky.social
Congrats to Ken Butcher on successfully leading the ICH-ADAPT 2 RCT. Our results do not support the notion that BP lowering contributes to the majority of acute/subacute DWI lesions in patients with ICH. Alternative mechanisms need to be explored. #ISC2025
@ahascience.bsky.social
For those who were unable to attend our update on best practices for managing ICH at #ISC2025, you can find the recording below:
www.youtube.com/watch?v=PiCn...
@christoslazaridis.bsky.social
ISC 2025
AHA/ASA Journals are on the ground at #ISC25
Check out the latest at www.ahajournals.org/isc
Should patients with #stroke and device-detected subclinical #AFib (SCAF) be treated with OAC?
Our subgroup analyses of the ARTESIA RCT (@thelancet.bsky.social) provide novel insights indicating that OAC is beneficial in appropriately selected patients.
www.thelancet.com/journals/lan...
WSO (@worldstrokeorg.bsky.social) Global ICH Factsheet
journals.sagepub.com/doi/full/10....
Congratulation to Dr. Sashi Perera on leading this important phase II RCT suggesting reduced rates of ischemic cerebrovascular events with dual pathway inhibition (rivaroxaban+ASA) in patients with ICAD.
www.ahajournals.org/doi/10.1161/...
@macdeptmed.bsky.social @ahascience.bsky.social
Thrilled to announce that the #EnrichAF randomized trial completed enrolment of 948 patients in Q4 2024.
So grateful for the efforts of our global colleagues on reaching this milestone, who persevered despite many challenges along the way.
Follow-up is due to complete in Q1 2026. Stay tuned!
See our recent @worldstrokeorg.bsky.social scientific statement on secondary #stroke prevention in patients w #Afib. Big thanks Dr. Luciano Sposato for taking on the lion's share of work for this important piece.
@macdeptmed.bsky.social
journals.sagepub.com/doi/10.1177/...
🎉 Exciting News! 🎉
We are thrilled to announce that Dr. Deborah Siegal has been appointed as the next Co-Director of CanVECTOR (joining Co-Director Dr. Grégoire Le Gal), starting April 1, 2025!
Learn more: 🔗
buff.ly/4gHeS1a
#Research #Thrombosis #VTE
Kudos to Dr. Lauren Mai from @westernu.bsky.social
on leading this insightful narrative review outlining the protracted recovery trajectory of patients with ICH.
www.ahajournals.org/doi/10.1161/...
@macdeptmed.bsky.social @harvardmed.bsky.social @ahajournals.bsky.social @ahascience.bsky.social